Kodiak Sciences Inc.

NasdaqGM KOD

Kodiak Sciences Inc. Shareholders' Equity for the quarter ending September 30, 2024

Kodiak Sciences Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Kodiak Sciences Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 302.42 M, a -36.93% change year over year.
Kodiak Sciences Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 479.53 M, a -33.98% change year over year.
Kodiak Sciences Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 726.32 M, a 157.76% change year over year.
Kodiak Sciences Inc. Shareholders' Equity for the quarter ending September 30, 2020 was USD 281.78 M, a 372.06% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGM: KOD

Kodiak Sciences Inc.

CEO	Dr. Victor Perlroth M.D.
IPO Date	Oct. 4, 2018
Location	United States
Headquarters	1200 Page Mill Road
Employees	111
Sector	Consumer Discretionary
Industries Eyewear 3D Printing Augmented Reality (AR) Biotechnology Clinical Trials Glass Pharmaceuticals Vaccines

Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Key trends

Past 5 years